Search Result

Results for "

arterial

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Adenosine Receptor (2) Adrenergic Receptor (7) Akt (4) Aldehyde Dehydrogenase (ALDH) (1) AMPK (1) Angiotensin Receptor (5) Angiotensin-converting Enzyme (ACE) (7) Antibiotic (2) Apelin Receptor (APJ) (4) Apoptosis (15) Arginase (1) Arrestin (2) Autophagy (1) Bacterial (3) Biochemical Assay Reagents (1) Bradykinin Receptor (1) c-Fms (1) c-Kit (1) Calcium Channel (3) CGRP Receptor (2) CMV (1) DNA Alkylator/Crosslinker (1) Dopamine Receptor (3) Drug Derivative (5) Drug Metabolite (7) E1/E2/E3 Enzyme (2) Elastase (1) Endogenous Metabolite (7) Endothelin Receptor (7) ERK (1) Estrogen Receptor/ERR (3) Factor Xa (2) Factor XI (2) Flavivirus (3) GABA Receptor (1) Glutaminase (1) Heme Oxygenase (HO) (1) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (1) HSP (1) Integrin (10) Isotope-Labeled Compounds (4) mAChR (4) N-myristoyltransferase (1) Neurokinin Receptor (2) NF-κB (3) NKCC (1) NO Synthase (2) Orthopoxvirus (1) P2Y Receptor (1) p38 MAPK (3) PARP (2) PDGFR (2) Phosphodiesterase (PDE) (13) PI3K (1) PKC (1) PKG (3) Potassium Channel (1) PPAR (2) Prostaglandin Receptor (15) Protease Activated Receptor (PAR) (1) Reactive Oxygen Species (3) Renin (3) SARS-CoV (2) Ser/Thr Protease (3) SOD (1) STAT (1) TGF-β Receptor (5) Thrombin (9) TNF Receptor (3) Transmembrane Glycoprotein (1) Tryptophan Hydroxylase (1) Vasopressin Receptor (4)
By Research Areas:	Cancer (21) Cardiovascular Disease (136) Endocrinology (7) Infection (9) Inflammation/Immunology (24) Metabolic Disease (21) Neurological Disease (12)
Click Chemistry:	Azide (1) Alkynes (1)
Oligonucleotides:	Aptamers (4)

180

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2299

Morusinol	Others	Cardiovascular Disease
Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and significantly inhibits arterial thrombosis in vivo .

HY-B1363

Bendroflumethiazide Bendrofluazide	Others	Cardiovascular Disease
Bendroflumethiazide is an orally active diuretic. Bendroflumethiazide is an antihypertensive agent. Bendroflumethiazide has the potential for the research of arterial hypertensive disease .

HY-148670

*Pulmonary arterial* hypertension agent-1**	Others	Cardiovascular Disease
Pulmonary arterial hypertension agent-1 (example 15) is a pulmonary arterial hypertension agent . Pulmonary arterial hypertension agent-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19229

TAK-029	Integrin	Cardiovascular Disease
TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .

HY-113547

Nanterinone UK 61260	Phosphodiesterase (PDE)	Cardiovascular Disease
Nanterinone (UK 61260) is a positive inotropic and arterial vasodilating agent. Nanterinone is a phosphodiesterase inhibitor .

HY-N1115

Tubotaiwine (+)-Tubotaiwine; NSC 306222; Tubotaiwin	Others	Cardiovascular Disease
Tubotaiwine ((+)-Tubotaiwine), an alkaloid, has beneficial effect on cadmium (Cd) induced hypertension in rats. Tubotaiwine regulates systolic, diastolic and mean arterial blood pressure of the Cd exposed rats. Tubotaiwine reduces arterial stiffness, inhibits of oxidative stress and increases vascular remodeling .

HY-117561

DuP 714	Thrombin	Cardiovascular Disease
DuP 714 is an oral active thrombin inhibitor with the IC₅₀ values of 150 nM aganist thrombin-induced aggregation in washed human platelets. DuP 714 can be used for study of arterial thrombosi .

HY-19219A

BMS-189664 hydrochloride	Thrombin	Cardiovascular Disease
BMS-189664 hydrochloride is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 hydrochloride can be used for arterial and venous thrombosis research .

HY-19219

BMS-189664	Thrombin	Cardiovascular Disease
BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research .

HY-19660

Inogatran H-314-27	Thrombin	Cardiovascular Disease
Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

HY-116457

Propanidid Sombrevin; Fabantol	GABA Receptor	Cardiovascular Disease Neurological Disease
Propanidid (Sombrevin; Fabantol) is a γ-aminobutyric acid type A (GABA_A) receptor agonist and a short-acting non-barbiturate general agent that can suppress or relieve pain. Propanidid can decrease the arterial pressure .

HY-P2021

BMS 180742	Thrombin	Cardiovascular Disease
BMS 180742 is a thrombin exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .

HY-117928

BRL 55834	Potassium Channel	Cardiovascular Disease
BRL 55834 is an orally and potent potassium channel activator. BRL 55834 exhibits great bronchodilator potency but reduces tendency to lower arterial blood pressure. BRL 55834 has the potential to use as a bronchodilator .

HY-170419

APJ receptor agonist 10	Apelin Receptor (APJ)	Cardiovascular Disease
APJ receptor agonist 10 (Compound I choline salt) modulates the activity of APJ receptor and can be used in research about pulmonary arterial hypertension. APJ receptor agonist 10 exhibits good bioavailability other than its free base form .

HY-109190

Seralutinib 1 Publications Verification GB002; PK10571	PDGFR c-Fms c-Kit	Cardiovascular Disease
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC₅₀s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .

HY-B1363R

Bendroflumethiazide (Standard)	NKCC	Cardiovascular Disease
Bendroflumethiazide (Standard) is the analytical standard of Bendroflumethiazide. This product is intended for research and analytical applications. Bendroflumethiazide is an orally active diuretic. Bendroflumethiazide is an antihypertensive agent. Bendroflumethiazide has the potential for the research of arterial hypertensive disease .

HY-121025

BUR1	TGF-β Receptor	Others
BUR1 is a BMP upregulator (EC₅₀: 98 nM) and activates BMPRII signalling. BUR1 induces BMP2 and PTGS2 expression. BUR1 reversed pulmonary arterial pressure in Monocrotaline (HY-N0750) induced rats .

HY-117805

UR-7247	Angiotensin Receptor	Cardiovascular Disease
UR-7247 is a potent and orally active angiotensin II AT1 receptor antagonist. UR-7247 decreases arterial pressure and increases renal blood flow .

HY-105686

FR-229934	Phosphodiesterase (PDE)	Cardiovascular Disease
FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction .

HY-154970

BMPR2-IN-1	TGF-β Receptor	Cancer
BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC₅₀ of 506 nM and a K_D of 83.5 nM. BMPR2-IN-1 can be used for research of pulmonary arterial hypertension, Alzheimer’s disease and cancer .

HY-154970A

BMPR2-IN-1 TFA	TGF-β Receptor	Cancer
BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC₅₀ of 506 nM and a K_D of 83.5 nM. BMPR2-IN-1 can be used for research of pulmonary arterial hypertension, Alzheimer’s disease and cancer .

HY-P3227

Cyclo(Ala-Arg-Gly-Asp-Mamb) XJ735	Integrin	Inflammation/Immunology
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension Research .

HY-D0199

Adenosine 5'-diphosphate disodium 1 Publications Verification	Endogenous Metabolite	Cardiovascular Disease
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-B0302

Etidronic acid 1 Publications Verification Etidronate; HEDPA; HEDP	Apoptosis	Metabolic Disease Cancer
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .

HY-107354

Gepefrine	Drug Derivative	Cardiovascular Disease
Gepefrine is an orally active pressor agent and sympathomimetic agent. Gepefrine improves the early orthostatic disregulation of the arterial pressure .

HY-117568

A-80b	Calcium Channel	Cardiovascular Disease
A-80b is a pyridazino[4,5-b]indole derivate. A 80b showsantihypertensive activity and can be used for study of Arterial hypertension .

HY-172094

AMPK-IN-6	AMPK Apoptosis Autophagy	Cardiovascular Disease
AMPK-IN-6 (compound 13a) is potent AMPK inhibitor with an IC₅₀ value of 0.093 µM. AMPK-IN-6 induces apoptosis and inhibits autophagy. AMPK-IN-6 shows antiproliferative activity. AMPK-IN-6 has the potential for the research of pulmonary arterial hypertension .

HY-153248

PBR28	Others	Others
PBR28 is an TSPO modulator, which can be used for prevention research of Pulmonary Arterial Hypertension (PAH). PBR28 can be used to trace 18 KDa transporter (TSPO) by adding radioactive labeling, which plays an important role in brain positron emission tomography (PET) imaging studies .

HY-B0464A

Hydralazine	Reactive Oxygen Species	Cardiovascular Disease Inflammation/Immunology Cancer
Hydralazine is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine has antioxidant activity, as well as inhibits reactive oxygen species (ROS) release and O₂ ^·- generation with an IC₅₀ value of 9.53 mM and 1.19 mM, respectively .

HY-150793

SY-LB-57	TGF-β Receptor	Cardiovascular Disease Neurological Disease
SY-LB-57 is a highly potent bone morphogenetic protein (BMP) receptor signaling agonist. SY-LB-57 can be used in studies of diseases such as fractures and pulmonary arterial hypertension .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .

HY-111348

Lamifiban Ro 44-9883	Integrin	Cardiovascular Disease
Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes .

HY-114961

15-epi Prostaglandin A1 15-epi PGA1	Prostaglandin Receptor	Cardiovascular Disease
15-epi Prostaglandin A1 (15-epi PGA1) is the 15(R) stereoisomer of PGA1. PGA1 causes renal vasodilation, increased urine sodium excretion, and decreased arterial pressure in hypertensive models .

HY-129782

SC-55858	SOD	Cardiovascular Disease
SC-55858 is an effective superoxide dismutase simulator. SC-55858 increased heart rate and decreased mean arterial pressure and left ventricular systolic and end-diastolic pressures in conscious dogs .

HY-122592

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

HY-111348A

Lamifiban TFA	Integrin	Cardiovascular Disease
Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes .

HY-162888

WQ-C-401	PDGFR ERK	Cardiovascular Disease
WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC₅₀ values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension .

HY-14184

Macitentan 10+ Cited Publications ACT-064992	Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-124124

N-Methylnicotinamide 1 Publications Verification	Endogenous Metabolite Drug Metabolite	Cardiovascular Disease Metabolic Disease Cancer
N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway. N-Methylnicotinamide is a potential biomarker in miR-1291-altered pancreatic cell metabolism and tumorigenesis .

HY-14184S

Macitentan-d4 ACT-064992-d₄	Isotope-Labeled Compounds Endothelin Receptor Apoptosis	Cardiovascular Disease
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].

HY-B2078A

Eprazinone dihydrochloride	Neurokinin Receptor	Inflammation/Immunology
Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a neurokinin 1 receptor (NK1R) ligand. Eprazinone dihydrochloride has the potential for chronic bronchitis treatment that improved pulmonary function and arterial partial pressure of oxygen .

HY-107655

Arecaidine but-2-ynyl ester tosylate ABET	mAChR	Cardiovascular Disease
Arecaidine but-2-ynyl ester tosylate (ABET) is a selective mAChR M2 agonist that dose-dependently decreases mean arterial pressure and heart rate in rats. Arecaidine but-2-ynyl ester tosylate can be used for cardiovascular disease research . Arecaidine but-2-ynyl ester (tosylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-90009

Nortadalafil Demethyl Tadalafil	Phosphodiesterase (PDE)	Cardiovascular Disease
Nortadalafil (Demethyl Tadalafil), a tadalafil (HY-90009A) analogue detected in health foods, is a highly selective PDE5 inhibitor. Nortadalafil is used in the research of erectile dysfunction (ED). Nortadalafil can be formed by closing the diketopiperazine ring in high yield. Nortadalafil is promising for research of pulmonary arterial hypertension .

HY-13569A

Beraprost sodium TRK-100; ML 1129 sodium	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost sodium (TRK-100), a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium (TRK-100) is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost sodium (TRK-100) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-118765

Ro 23-3423	Prostaglandin Receptor	Cardiovascular Disease
Ro 23-3423 is a thromboxane synthase inhibitor with an IC₅₀ value of 0.33 μM for human platelet microsomal thromboxane synthase. Ro 23-3423 increases plasma levels of PGF and PGE2 in a dose-dependent manner, accompanied by a decrease in mean systemic arterial pressure and systemic vascular resistance. Ro 23-3423 can be used in the study of general anesthesia .

HY-13569AR

Beraprost (sodium) (Standard)	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost (sodium) (Standard) is the analytical standard of Beraprost (sodium). This product is intended for research and analytical applications. Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14184R

Macitentan (Standard)	Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-170435

PDE5-IN-13	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC₅₀ of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active .

HY-90009R

Nortadalafil (Standard)	Phosphodiesterase (PDE)	Cardiovascular Disease
Nortadalafil (Standard) is the analytical standard of Nortadalafil. This product is intended for research and analytical applications. Nortadalafil , a new tadalafil (HY-90009A) analogue detected in health foods, is a PDE5 inhibitor. Nortadalafil is used in the research of erectile dysfunction (ED). Nortadalafil can be formed by closing the diketopiperazine ring in high yield. Nortadalafil is promising for research of pulmonary arterial hypertension [4] .

HY-155737

ET receptor antagonist 1	Estrogen Receptor/ERR	Cardiovascular Disease
ET receptor antagonist 1 (compound 16h) is an orally active ET receptor antagonist (IC₅₀=0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 1 attenuates monocrotaline (HY-N0750) induced PAH in rat model .

Cat. No.	Product Name

HY-L046

Anti-Cardiovascular Disease Compound Library

1,807 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 1,807 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

HY-L145

Antihypertensive Compound Library

698 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 698 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Cat. No.	Product Name	Type

HY-D0199

Adenosine 5'-diphosphate disodium 1 Publications Verification	Biochemical Assay Reagents
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

Cat. No.	Product Name	Target	Research Area

HY-P1534

Adrenomedullin (1-50), rat	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (1-50), rat is a 50 amino acid peptide, which induces a selective arterial vasodilation via activation of CGRP1 receptor.

HY-P0012A

Aviptadil acetate 1 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P2021

BMS 180742	Thrombin	Cardiovascular Disease
BMS 180742 is a thrombin exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .

HY-P3227

Cyclo(Ala-Arg-Gly-Asp-Mamb) XJ735	Integrin	Inflammation/Immunology
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension Research .

HY-P5951

Adrenomedullin (1-12) (human)	Peptides	Cardiovascular Disease
Adrenomedullin (1-12) (human) is adrenomedullin fragment. Adrenomedullin has no effect on arterial pressure in cats

HY-P1766

Adrenomedullin (11-50), rat	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (11-50), rat is the C-terminal fragment (11-50) of rat adrenomedullin. Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors .

HY-P10092

SP6	Akt NO Synthase PI3K	Cardiovascular Disease
SP6 exertes an antihypertensive effect through vascular NO regulation .

HY-P3593

LPLRF-NH2	Calcium Channel	Cardiovascular Disease Neurological Disease
LPLRF-NH2 is a member of RFamide peptide with anorexigenic effect. LPLRF-NH2 increases arterial blood pressure and modulates the electrical activity of brainstem neurons .

HY-P3765

Auriculin A	Peptides	Cardiovascular Disease
Auriculin A is a synthetic atrial natriuretic factor (ANF) with hemodynamic effect. Auriculin A antagonizes renal vasoconstriction in the dog, and influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits .

HY-P1694

B4148	Bradykinin Receptor	Cardiovascular Disease
B4148 is a selective competitive bradykinin (BK) antagonist that significantly inhibits BK-induced hypotension in rats. In a rat model of endotoxin shock induced by Escherichia coli lipopolysaccharide, B4148 significantly attenuated the decrease in mean arterial blood pressure compared with the control group .

HY-P0012

Aviptadil 1 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P2106

Elabela(19-32) 4 Publications Verification	Arrestin Apelin Receptor (APJ)	Cardiovascular Disease
Elabela(19-32) is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) activates the G_αi1 and β-arrestin-2 signaling pathways with EC₅₀s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .

HY-P1556

Vasonatrin Peptide (VNP)	PKG	Cardiovascular Disease
Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-P2106A

Elabela(19-32) TFA 4 Publications Verification	Apelin Receptor (APJ) Arrestin	Cardiovascular Disease
Elabela(19-32) TFA is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) TFA activates the G_αi1 and β-arrestin-2 signaling pathways with EC₅₀s of 8.6 nM and 166 nM. Elabela(19-32) TFA induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .

HY-P1556A

Vasonatrin Peptide (VNP) TFA	PKG	Metabolic Disease
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-P4683A

(Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin acetate	Vasopressin Receptor	Cardiovascular Disease
(Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin is a potent vasopressin V1 receptor (VP V1R) antagonist. (Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin significantly decreases the mean arterial pressure (MAP) in rats .

HY-P4683

(Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin	Vasopressin Receptor	Cardiovascular Disease
(Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin is a potent vasopressin V1 receptor (VP V1R) antagonist. (Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin significantly decreases the mean arterial pressure (MAP) in rats .

Cat. No.	Product Name	Target	Research Area

HY-P99590

Sotatercept ACE-011	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2299

Morusinol	Cardiovascular Disease Flavonoids Classification of Application Fields Flavones Source classification Phenols Polyphenols Plants Moraceae Disease Research Fields Morus alba Linn.	Others
Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and significantly inhibits arterial thrombosis in vivo .

HY-D0199

Adenosine 5'-diphosphate disodium 1 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-124124

N-Methylnicotinamide 1 Publications Verification	Alkaloids Structural Classification Classification of Application Fields Source classification Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Drug Metabolite
N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway. N-Methylnicotinamide is a potential biomarker in miR-1291-altered pancreatic cell metabolism and tumorigenesis .

HY-119358

Traumatic Acid 2 Publications Verification	Structural Classification Classification of Application Fields Source classification Plants Phaseolus vulgaris Linn. Cytokinin Agricultural Research Microorganisms Leguminosae Ketones, Aldehydes, Acids Phytohormone Inflammation/Immunology Disease Research Fields	Reactive Oxygen Species Apoptosis
Traumatic Acid is a wound healing agent and a cytokinin (phytohormone). Traumatic Acid enhances the biosynthesis of collagen in cultured human skin fibroblasts. Traumatic Acid inhibits MCF-7 breast cancer cells viability and enhances apoptosis and oxidative stress. Traumatic Acid can be used in studies of cancer, circulatory disorders (including arterial hypertension), and skin diseases associated with oxidative stress and impaired collagen biosynthesis .

HY-122365

Inositol nicotinate Inositol niacinate; Hexanicit	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Drug Derivative
Inositol nicotinate (Hexanicit) has vasodilating effects and can be used in research on peripheral arterial disease, showing efficacy when taken orally. Inositol nicotinate does not significantly improve triglyceride levels in mice induced by biphenyl esters .

HY-A0126A

Epoprostenol sodium Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Apoptosis
Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-124489

2-Hydroxyestradiol 1 Publications Verification	Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .

HY-N0750

Monocrotaline Maximum Cited Publications 33 Publications Verification Crotaline	Structural Classification Alkaloids Pyrrole Alkaloids Classification of Application Fields Leguminosae Crotalaria pallida Ait. Plants Disease Research Fields Cancer	Others
Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC₅₀s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. ^[2][6][8].

HY-N1115

Tubotaiwine (+)-Tubotaiwine; NSC 306222; Tubotaiwin	Apocynaceae Structural Classification Alkaloids Other Alkaloids Source classification Hunteria zeylanica Plants	Others
Tubotaiwine ((+)-Tubotaiwine), an alkaloid, has beneficial effect on cadmium (Cd) induced hypertension in rats. Tubotaiwine regulates systolic, diastolic and mean arterial blood pressure of the Cd exposed rats. Tubotaiwine reduces arterial stiffness, inhibits of oxidative stress and increases vascular remodeling .

HY-119358R

Traumatic Acid (Standard)	Structural Classification Microorganisms Leguminosae Ketones, Aldehydes, Acids Source classification Plants Phaseolus vulgaris Linn.	Reactive Oxygen Species Apoptosis

Cat. No.	Product Name	Chemical Structure

HY-14184S

Macitentan-d4
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].

HY-90009S

Tadalafil-d3
Tadalafil-d₃ is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.

HY-113331S1

Thromboxane B2-d9
Thromboxane B2-d₉ is deuterium labeled Thromboxane B2. Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation .

HY-113331S

Thromboxane B2-d4
Thromboxane B2-D4 is the deuterium labeled Thromboxane B2. Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation .

HY-12765S1

Losartan carboxylic acid-d4 hydrochloride

Losartan carboxylic acid-d₄ (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure[1][2][3][4].

Cat. No.	Product Name		Classification

HY-129737

A-62198		Azide
A-62198 is a potent and selective renin inhibitor with antihypertensive activity. A-62198 reduces mean arterial pressure (MAP) in anesthetized, salt-deprived monkeys in a dose-dependent manner. A-62198 induced MAP reduction in normal monkeys that reached statistical significance at the highest dose and significantly inhibited plasma renin activity (PRA) at all doses .

HY-134061

Arecaidine propargyl ester hydrobromide		Alkynes
Arecaidine propargyl ester hydrobromide is an agonist of M2 muscarinic acetylcholine receptors and has the activity of inhibiting tumor cell proliferation. The application of arecaidine propargyl ester hydrobromide has shown that it can reduce the number of ovarian cancer cells in vitro and induce apoptosis and the production of reactive oxygen species (ROS) at specific concentrations. Arecaidine propargyl ester hydrobromide can also arrest cells at the G2/M phase of the cell cycle and increase the percentage of abnormal mitosis. Arecaidine propargyl ester hydrobromide is more sensitizing to ovarian surface epithelial cells with higher M2 receptor levels than to cancer cells. Arecaidine propargyl ester hydrobromide exhibits the effect of lowering arterial blood pressure when interacting with the cardiovascular system in a natural physiological state, indicating its potential pharmacological application .

Cat. No.	Product Name		Classification

HY-153999A

BT200 sodium		Aptamers
BT200 sodium, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-153998

BT100 sodium		Aptamers
BT100 (sodium), a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-153999

BT200		Aptamers
BT200, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-156501

BT101 sodium		Aptamers
BT101 (sodium), a complementary aptamer, has been developed to specifically inhibit BT100 function. BT100, a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

arterial

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products